Cidofovir in the Management of Non-Genital Warts: A Review
Conclusion: Treatment options for recalcitrant non-genital warts are limited and have varying efficacy. Topical cidofovir may serve as an effective, safe, and affordable alternative for the clearance of recalcitrant non-genital warts, but controlled clinical trials are needed.J Drugs Dermatol. 2023;22(10):1009-1016 doi:10.36849/JDD.7258.PMID:37801536 | DOI:10.36849/JDD.7258 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Madison K Cook Erin M Hagen Steven R Feldman Source Type: research
Barriers and facilitators to anal cancer screening among people living with HIV in Puerto Rico
CONCLUSIONS: With emerging evidence on the effectiveness of screening and treatment for anal cancer, several organizations are steering toward generating consensus-based anal cancer screening recommendations. Our study provides foundational data on barriers and facilitators to anal cancer screening in Puerto Rico that will be critical to informing screening implementation in this US territory.PMID:37803344 | PMC:PMC10559598 | DOI:10.1186/s12889-023-16847-6 (Source: Cancer Control)
Source: Cancer Control - October 6, 2023 Category: Cancer & Oncology Authors: Gabriela Cruz Jeslie M Ramos-Cartagena Jos é L Torres-Russe Vivian Col ón-López Karen J Ortiz-Ortiz Luis Pericchi Ashish A Deshmukh Ana Patricia Ortiz Source Type: research
Cidofovir in the Management of Non-Genital Warts: A Review
Conclusion: Treatment options for recalcitrant non-genital warts are limited and have varying efficacy. Topical cidofovir may serve as an effective, safe, and affordable alternative for the clearance of recalcitrant non-genital warts, but controlled clinical trials are needed.J Drugs Dermatol. 2023;22(10):1009-1016 doi:10.36849/JDD.7258.PMID:37801536 | DOI:10.36849/JDD.7258 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Madison K Cook Erin M Hagen Steven R Feldman Source Type: research
A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
BACKGROUND Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations. Myelokathexis is a kind of neutropenia caused by neutrophil retention in bone marrow and in WHIM syndrome is associated with lymphopenia and monocytopenia. The CXCR4 antagonist plerixafor mobilizes leukocytes to the blood; however, its safety and efficacy in WHIM syndrome are undefined.METHODS In this investigator-initiated, single-center, quadruple-masked phase III crossover trial, we compared the total infection severity score (TISS) as the ...
Source: Journal of Clinical Investigation - October 3, 2023 Category: Biomedical Science Authors: David H. McDermott, Daniel Velez, Elena Cho, Edward W. Cowen, John J. DiGiovanna, Diana V. Pastrana, Christopher B. Buck, Katherine R. Calvo, Pamela J. Gardner, Sergio D. Rosenzweig, Pamela Stratton, Melissa A. Merideth, H. Jeffrey Kim, Carmen Brewer, Jam Source Type: research
